The proof of concept demonstrated by targeting the STING pathway with an orally bioactive STING antagonist VS-X4 paves new avenues for therapeutic interventions, not only for NGLY1 deficiency but also for other neurodegenerative diseases involving the STING pathway. The gene discussed is NGLY1; the disease is neurodegenerative disease.